(-0.15%) 5 205.00 points
(-0.11%) 39 150 points
(-0.23%) 18 146 points
(0.49%) $79.38
(0.37%) $2.20
(-0.02%) $2 321.90
(0.97%) $27.87
(0.65%) $991.00
(0.08%) $0.931
(0.15%) $10.91
(0.08%) $0.801
(0.28%) $91.99
-0.93% $ 5.93
Live Chart Being Loaded With Signals
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands...
Stats | |
---|---|
Dzisiejszy wolumen | 2 273.00 |
Średni wolumen | 10 418.00 |
Kapitalizacja rynkowa | 3.75B |
EPS | $0.782 ( 2023-09-30 ) |
Następna data zysków | ( $0 ) 2024-07-25 |
Last Dividend | $0.0640 ( 2023-07-06 ) |
Next Dividend | $0 ( N/A ) |
P/E | 11.19 |
ATR14 | $0 (0.00%) |
Hypera S.A. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Hypera S.A. Finanse
Annual | 2023 |
Przychody: | $7.91B |
Zysk brutto: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2023 |
Przychody: | $7.91B |
Zysk brutto: | $4.85B (61.30 %) |
EPS: | $2.61 |
FY | 2022 |
Przychody: | $7.55B |
Zysk brutto: | $4.76B (63.10 %) |
EPS: | $2.68 |
FY | 2021 |
Przychody: | $5.94B |
Zysk brutto: | $3.80B (64.05 %) |
EPS: | $2.11 |
Financial Reports:
No articles found.
Hypera S.A. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0590 (N/A) |
$0.117 (N/A) |
$0 (N/A) |
$0.0590 (N/A) |
$0.0640 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0770 | 2011-05-10 |
Last Dividend | $0.0640 | 2023-07-06 |
Next Dividend | $0 | N/A |
Payout Date | 2023-09-09 | |
Next Payout Date | N/A | |
# dividends | 30 | -- |
Total Paid Out | $2.45 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.13 | -- |
Div. Sustainability Score | 9.59 | |
Div.Growth Potential Score | 5.92 | |
Div. Directional Score | 7.75 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
THVB | Ex Dividend Knight | 2023-06-14 | Semi-Annually | 0 | 0.00% | |
HMLN | Ex Dividend Junior | 2023-06-13 | Annually | 0 | 0.00% | |
ANPDY | Ex Dividend Knight | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
PFLC | Ex Dividend Knight | 2023-08-10 | Quarterly | 0 | 0.00% | |
DBOEY | Ex Dividend Junior | 2023-05-17 | Annually | 0 | 0.00% | |
UOVEY | Ex Dividend Knight | 2023-08-04 | Annually | 0 | 0.00% | |
JMPLY | Ex Dividend Junior | 2023-06-15 | Semi-Annually | 0 | 0.00% | |
BHWB | Ex Dividend Knight | 2023-07-27 | Quarterly | 0 | 0.00% | |
RSTRF | Ex Dividend Knight | 2023-09-19 | Semi-Annually | 0 | 0.00% | |
ERMAY | Ex Dividend Junior | 2023-05-25 | Sporadic | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.212 | 1.500 | 5.77 | 8.65 | [0 - 0.5] |
returnOnAssetsTTM | 0.0604 | 1.200 | 7.99 | 9.58 | [0 - 0.3] |
returnOnEquityTTM | 0.149 | 1.500 | 9.45 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.0801 | -1.000 | 9.20 | -9.20 | [0 - 1] |
currentRatioTTM | 1.807 | 0.800 | 5.97 | 4.77 | [1 - 3] |
quickRatioTTM | 1.314 | 0.800 | 6.98 | 5.58 | [0.8 - 2.5] |
cashRatioTTM | 0.662 | 1.500 | 7.43 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.378 | -1.500 | 3.69 | -5.54 | [0 - 0.6] |
interestCoverageTTM | 2.28 | 1.000 | -0.266 | -0.266 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.07 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.910 | -1.500 | 6.36 | -9.54 | [0 - 2.5] |
grossProfitMarginTTM | 0.615 | 1.000 | 3.09 | 3.09 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.327 | 1.000 | 5.45 | 5.45 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.183 | 1.000 | -0.0935 | -0.0935 | [0.2 - 2] |
assetTurnoverTTM | 0.286 | 0.800 | -1.429 | -1.143 | [0.5 - 2] |
Total Score | 9.59 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 11.30 | 1.000 | 8.96 | 0 | [1 - 100] |
returnOnEquityTTM | 0.149 | 2.50 | 9.65 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.866 | 2.00 | 9.38 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.176 | 1.500 | 5.60 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.08 | 2.00 | 8.97 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.0801 | 1.500 | 9.20 | -9.20 | [0 - 1] |
pegRatioTTM | 0.0397 | 1.500 | -3.07 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.243 | 1.000 | 6.43 | 0 | [0.1 - 0.5] |
Total Score | 5.92 |
Hypera S.A.
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej